Malaria elimination requires new drugs, faster approvals –Expert

Global efforts to eradicate malaria face an urgent inflection point, as escalating drug resistance and a critical funding deficit threaten to reverse decades of progress. Dr. Timothy Wells, Chief Scientific Officer of Medicines for Malaria Venture (MMV), recently underscored the desperate need for novel antimalarial drugs and expedited regulatory approvals to outpace the evolving parasite and avert a catastrophic resurgence of the disease. His remarks come amidst new data highlighting the complex multi-locus nature of existing drug resistance, making current treatments increasingly vulnerable. The stakes are higher than ever: the World Health Organization reported a slight increase to 282 million malaria cases and 610,000 deaths in 2024, with Africa bearing 95% of the mortality burden. Contributing to this dire situation is a staggering funding gap, with 2024 investments hitting less than half of the required $9.3 billion 2025 target, coupled with pervasive insecticide resistance, compromised diagnostic accuracy from pfhrp2 gene deletions, and a rapidly expanding geographical footprint driven by climate change. The latest research projects climate change could add over 100 million cases and 500,000 deaths in Africa by 2050, largely due to extreme weather disrupting control efforts. However, a glimmer of hope emerges from a robust pipeline of innovations. Novartis's ganaplacide/lumefantrine recently showed promising Phase III results, while Portland State University unveiled T111, a drug candidate designed for single-encounter treatment across all parasite stages. MMV, in collaboration with other Product Development Partnerships like DNDi and GARDP, is also pushing for long-acting injectables and launching a joint regulatory science platform in 2026 to streamline approvals, ensuring these critical new tools reach patients in endemic regions faster. The coming years will reveal if these scientific advancements and strategic collaborations can overcome the compounding global health crises and finally turn the tide against malaria.